RU2009141359A - Посттерапевтический прогноз выживания больных раком с использованием микрорнк - Google Patents
Посттерапевтический прогноз выживания больных раком с использованием микрорнк Download PDFInfo
- Publication number
- RU2009141359A RU2009141359A RU2009141359/14A RU2009141359A RU2009141359A RU 2009141359 A RU2009141359 A RU 2009141359A RU 2009141359/14 A RU2009141359/14 A RU 2009141359/14A RU 2009141359 A RU2009141359 A RU 2009141359A RU 2009141359 A RU2009141359 A RU 2009141359A
- Authority
- RU
- Russia
- Prior art keywords
- hsa
- patient
- expression level
- post
- mir372
- Prior art date
Links
- 230000004083 survival effect Effects 0.000 title claims abstract 27
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 15
- 201000011510 cancer Diseases 0.000 title claims abstract 15
- 108091070501 miRNA Proteins 0.000 title claims abstract 10
- 238000000034 method Methods 0.000 claims abstract 35
- 108091068985 Homo sapiens miR-137 stem-loop Proteins 0.000 claims abstract 21
- 108091067572 Homo sapiens miR-221 stem-loop Proteins 0.000 claims abstract 21
- 108091067570 Homo sapiens miR-372 stem-loop Proteins 0.000 claims abstract 21
- 108091067627 Homo sapiens miR-182 stem-loop Proteins 0.000 claims abstract 18
- 239000002679 microRNA Substances 0.000 claims abstract 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract 6
- 108700011259 MicroRNAs Proteins 0.000 claims abstract 5
- 108091091807 let-7a stem-loop Proteins 0.000 claims abstract 5
- 108091057746 let-7a-4 stem-loop Proteins 0.000 claims abstract 5
- 108091028376 let-7a-5 stem-loop Proteins 0.000 claims abstract 5
- 108091024393 let-7a-6 stem-loop Proteins 0.000 claims abstract 5
- 108091091174 let-7a-7 stem-loop Proteins 0.000 claims abstract 5
- 206010006187 Breast cancer Diseases 0.000 claims abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 3
- 206010009944 Colon cancer Diseases 0.000 claims abstract 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 3
- 208000009956 adenocarcinoma Diseases 0.000 claims abstract 3
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract 3
- 208000032839 leukemia Diseases 0.000 claims abstract 3
- 201000005202 lung cancer Diseases 0.000 claims abstract 3
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract 3
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract 3
- 238000001959 radiotherapy Methods 0.000 claims abstract 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 3
- 238000001356 surgical procedure Methods 0.000 claims abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91099307P | 2007-04-10 | 2007-04-10 | |
| US60/910,993 | 2007-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009141359A true RU2009141359A (ru) | 2011-05-20 |
Family
ID=39831416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009141359/14A RU2009141359A (ru) | 2007-04-10 | 2008-04-09 | Посттерапевтический прогноз выживания больных раком с использованием микрорнк |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7745134B2 (enExample) |
| EP (1) | EP2134874A4 (enExample) |
| JP (1) | JP2010523156A (enExample) |
| KR (1) | KR20100027102A (enExample) |
| CN (1) | CN101688240A (enExample) |
| AU (1) | AU2008237036A1 (enExample) |
| CA (1) | CA2695868A1 (enExample) |
| CO (1) | CO6231056A2 (enExample) |
| IL (1) | IL201298A0 (enExample) |
| MX (1) | MX2009010899A (enExample) |
| RU (1) | RU2009141359A (enExample) |
| TW (1) | TWI367949B (enExample) |
| WO (1) | WO2008124777A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103866018B (zh) | 2005-08-01 | 2016-05-25 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
| CN103028120B (zh) | 2005-09-12 | 2015-08-12 | 俄亥俄州立大学研究基金会 | 用于诊断或治疗bcl2相关癌症的组合物和方法 |
| WO2007081720A2 (en) | 2006-01-05 | 2007-07-19 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
| ES2524018T3 (es) | 2006-01-05 | 2014-12-03 | The Ohio State University Research Foundation | Anomalías de la expresión de microARN en tumores pancreáticos endocrinos y acinares |
| EP2487260B1 (en) | 2006-01-05 | 2015-07-08 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
| EP2369012A1 (en) | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Micro-RNA fingerprints during human megakaryocytopoiesis |
| CA2657030A1 (en) | 2006-07-13 | 2008-01-17 | The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio | Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases |
| US8071292B2 (en) | 2006-09-19 | 2011-12-06 | The Ohio State University Research Foundation | Leukemia diagnostic methods |
| JP5501766B2 (ja) | 2006-11-01 | 2014-05-28 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン |
| US8034560B2 (en) | 2007-01-31 | 2011-10-11 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML) |
| CA2690144A1 (en) * | 2007-06-08 | 2008-12-18 | The Government Of The United States Of America As Represented By The Sec Retary Of Department Of Health And Human Services | Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells |
| US8053186B2 (en) | 2007-06-15 | 2011-11-08 | The Ohio State University Research Foundation | Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing |
| ES2496172T3 (es) | 2007-07-31 | 2014-09-18 | The Ohio State University Research Foundation | Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B |
| AU2008283997B2 (en) | 2007-08-03 | 2014-04-10 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncRNAs |
| CN101836112A (zh) | 2007-08-22 | 2010-09-15 | 俄亥俄州立大学研究基金会 | 用于在人急性白血病中诱导epha7和erk磷酸化的脱调节的方法和组合物 |
| CA2703707A1 (en) | 2007-10-26 | 2009-04-30 | The Ohio State University Research Foundation | Methods for identifying fragile histidine triad (fhit) interaction and uses thereof |
| AU2009257410B2 (en) | 2008-06-11 | 2014-03-06 | Fudan University | Use of miR-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy |
| WO2010054386A2 (en) * | 2008-11-10 | 2010-05-14 | Battelle Memorial Institute | Methods, compositions, and devices utilizing microrna to determine physiological conditions |
| US8729041B2 (en) | 2008-12-03 | 2014-05-20 | The Johns Hopkins University | Compositions and methods for treating hepatic neoplasia |
| EP2196543A1 (en) * | 2008-12-15 | 2010-06-16 | Koninklijke Philips Electronics N.V. | Compositions and methods for micro-rna expression profiling of hepatocellular cancer |
| WO2010094155A1 (en) * | 2009-02-23 | 2010-08-26 | Capitalbio Corporation | Methods and compositions diagnosing lung cancer, determining prognosis, and improving patient survival |
| CN101638656B (zh) * | 2009-08-28 | 2011-05-11 | 南京医科大学 | 一种与非小细胞肺癌预后相关的血清/血浆miRNA标志物及其应用 |
| JP5960060B2 (ja) | 2009-11-23 | 2016-08-02 | ジ・オハイオ・ステート・ユニバーシティ | 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法 |
| JP5763098B2 (ja) * | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| US20110223607A1 (en) | 2010-03-12 | 2011-09-15 | Quest Diagnostics Investments Incorporated | Circulating microrna as a marker for hepatocellular carcinoma |
| WO2012065049A1 (en) | 2010-11-12 | 2012-05-18 | The Ohio State University Research Foundation | Materials and methods related to microrna-21, mismatch repair, and colorectal cancer |
| CA2817982C (en) | 2010-11-15 | 2020-06-30 | The Regents Of The University Of Michigan | Controlled release mucoadhesive systems |
| US8664192B2 (en) | 2011-03-07 | 2014-03-04 | The Ohio State University | Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer |
| US8404437B2 (en) | 2011-03-29 | 2013-03-26 | Taipei Veterans General Hospital | MicroRNA as a cancer progression predictor and its use for treating cancer |
| US20140113978A1 (en) * | 2011-05-01 | 2014-04-24 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| EP2757154A4 (en) | 2011-09-16 | 2015-10-14 | Lsip Llc | METHOD FOR DETECTING BLOOD TUMOR CELLS, PRIMER FOR USE IN THIS METHOD FOR DETECTING BLOOD TUMOR CELLS AND BLADDER CANCER MARKERS |
| EP2766500A4 (en) | 2011-10-14 | 2015-10-14 | Univ Ohio State | METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER |
| CN104619353A (zh) | 2011-12-13 | 2015-05-13 | 俄亥俄州国家创新基金会 | 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移 |
| US9850541B2 (en) * | 2011-12-19 | 2017-12-26 | Valley Health System | Methods and kits for detecting subjects at risk of having cancer |
| JP2015511121A (ja) | 2012-01-20 | 2015-04-16 | ジ・オハイオ・ステート・ユニバーシティ | 浸潤性および予後に関する乳がんバイオマーカーシグネチャー |
| US8846316B2 (en) | 2012-04-30 | 2014-09-30 | Industrial Technology Research Institute | Biomarker for human liver cancer |
| US10738363B2 (en) | 2016-08-31 | 2020-08-11 | National Central University | Analyzer and analytical method for predicting prognosis of cancer radiotherapy |
| DE102018110526A1 (de) | 2018-05-02 | 2019-11-07 | Faurecia Autositze Gmbh | Verfahren zur Montage eines Linearaktuators für einen Kraftfahrzeugsitz |
| CN108630317B (zh) * | 2018-05-09 | 2022-04-15 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的肝癌个性化预后评估方法 |
| CN108320806B (zh) * | 2018-05-09 | 2022-04-12 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的结肠癌个性化预后评估方法 |
| CN108647493B (zh) * | 2018-05-09 | 2022-01-18 | 中国科学院昆明动物研究所 | 一种肾透明细胞癌个性化预后评估方法 |
| CN108470111B (zh) * | 2018-05-09 | 2022-01-18 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的胃癌个性化预后评估方法 |
| CN108611416B (zh) * | 2018-05-09 | 2020-12-29 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的宫颈癌个性化预后评估方法 |
| CN108733980B (zh) * | 2018-05-09 | 2022-01-18 | 中国科学院昆明动物研究所 | 基于多基因表达特征谱胶质母细胞瘤个性化预后评估方法 |
| CN108648826B (zh) * | 2018-05-09 | 2022-04-15 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的胰腺癌个性化预后评估方法 |
| CN108363907B (zh) * | 2018-05-09 | 2022-01-18 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的肺腺癌个性化预后评估方法 |
| US11410745B2 (en) * | 2018-06-18 | 2022-08-09 | International Business Machines Corporation | Determining potential cancer therapeutic targets by joint modeling of survival events |
| TWI758670B (zh) * | 2018-12-24 | 2022-03-21 | 奎克生技光電股份有限公司 | 健康風險評估方法 |
| CN111172285A (zh) * | 2020-02-26 | 2020-05-19 | 江南大学附属医院 | 用于胰腺癌早期诊断和/或预后监测的miRNA组及其应用 |
| TWI878107B (zh) * | 2024-04-30 | 2025-03-21 | 朱旆億 | 乳癌預後存活率預測模型建立方法及系統 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004029287A2 (en) * | 2002-09-27 | 2004-04-08 | Oridis Biomed Forschungs- Und Entwicklungs Gmbh | Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer |
| US20040152112A1 (en) * | 2002-11-13 | 2004-08-05 | Thomas Jefferson University | Compositions and methods for cancer diagnosis and therapy |
| CA2554818A1 (en) * | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features |
| US20050272067A1 (en) * | 2004-03-10 | 2005-12-08 | Macina Roberto A | Compositions, splice variants and methods relating to cancer specific genes and proteins |
| US20060078913A1 (en) * | 2004-07-16 | 2006-04-13 | Macina Roberto A | Compositions, splice variants and methods relating to cancer specific genes and proteins |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
-
2008
- 2008-04-09 EP EP08745383A patent/EP2134874A4/en not_active Withdrawn
- 2008-04-09 RU RU2009141359/14A patent/RU2009141359A/ru not_active Application Discontinuation
- 2008-04-09 AU AU2008237036A patent/AU2008237036A1/en not_active Abandoned
- 2008-04-09 WO PCT/US2008/059767 patent/WO2008124777A1/en not_active Ceased
- 2008-04-09 TW TW097112898A patent/TWI367949B/zh not_active IP Right Cessation
- 2008-04-09 US US12/100,113 patent/US7745134B2/en not_active Expired - Fee Related
- 2008-04-09 JP JP2010503183A patent/JP2010523156A/ja not_active Withdrawn
- 2008-04-09 CA CA2695868A patent/CA2695868A1/en not_active Abandoned
- 2008-04-09 MX MX2009010899A patent/MX2009010899A/es not_active Application Discontinuation
- 2008-04-09 CN CN200880011562A patent/CN101688240A/zh active Pending
- 2008-04-09 KR KR1020097023492A patent/KR20100027102A/ko not_active Withdrawn
-
2009
- 2009-10-01 IL IL201298A patent/IL201298A0/en unknown
- 2009-10-08 CO CO09111661A patent/CO6231056A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20080254473A1 (en) | 2008-10-16 |
| US7745134B2 (en) | 2010-06-29 |
| AU2008237036A2 (en) | 2010-09-09 |
| WO2008124777A1 (en) | 2008-10-16 |
| CN101688240A (zh) | 2010-03-31 |
| IL201298A0 (en) | 2010-05-31 |
| KR20100027102A (ko) | 2010-03-10 |
| AU2008237036A1 (en) | 2008-10-16 |
| EP2134874A1 (en) | 2009-12-23 |
| TWI367949B (en) | 2012-07-11 |
| EP2134874A4 (en) | 2010-12-22 |
| TW200912002A (en) | 2009-03-16 |
| MX2009010899A (es) | 2010-02-17 |
| JP2010523156A (ja) | 2010-07-15 |
| CO6231056A2 (es) | 2010-12-20 |
| CA2695868A1 (en) | 2008-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009141359A (ru) | Посттерапевтический прогноз выживания больных раком с использованием микрорнк | |
| US9745630B2 (en) | MiRNA fingerprint in the diagnosis of prostate cancer | |
| Shrivastava et al. | Up‐regulation of circulating miR‐20a is correlated with hepatitis C virus‐mediated liver disease progression | |
| Weissmann-Brenner et al. | Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer | |
| EP2336353A1 (en) | miRNA fingerprints in the diagnosis of diseases | |
| Mairinger et al. | Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study | |
| CN101921760B (zh) | 一种与乳腺癌相关的血清/血浆miRNA标志物及其应用 | |
| US20120219958A1 (en) | MicroRNA Signatures Differentiating Uterine and Ovarian Papillary Serous Tumors | |
| CN102776185B (zh) | 由血浆microRNA组合成的肝癌诊断标志物及一种诊断肝癌的新方法 | |
| Ye et al. | Long noncoding RNA bladder cancer associated transcript 1 promotes the proliferation, migration, and invasion of nonsmall cell lung cancer through sponging miR-144 | |
| AU2011311881A1 (en) | MicroRNAs (miRNA) as biomakers for the identification of familial and non-familial colorectal cancer | |
| White et al. | Dysregulation of kallikrein-related peptidases in renal cell carcinoma: potential targets of miRNAs | |
| Guo et al. | Identification of miRNAs that are associated with tumor metastasis in neuroblastoma | |
| Osaka et al. | MicroRNA-155 expression is independently predictive of outcome in chordoma | |
| Jing et al. | Reduced miR-485-5p expression predicts poor prognosis in patients with gastric cancer | |
| Chen et al. | Circulating miR-148b-3p and miR-409-3p as biomarkers for heart failure in patients with mitral regurgitation | |
| Venza et al. | Identification of microRNA expression patterns in cutaneous and uveal melanoma cell lines | |
| Naeini et al. | Noncoding RNAs and cancer | |
| Shi et al. | Upregulation of miR-522 is associated with poor outcome of hepatocellular carcinoma | |
| Ricciardiello et al. | A miRNA signature suggestive of nodal metastases from laryngeal carcinoma | |
| Zheng et al. | MircoRNA-629 promotes proliferation, invasion and migration of nasopharyngeal carcinoma through targeting PDCD4. | |
| EP3862442A2 (en) | Method for the early diagnosis of cancer by means of ddpcr analysis of mirna in liquid biopsy | |
| Lijing et al. | Differential expressions of microRNAs in rectal adenocarcinoma tissues | |
| KR20170021580A (ko) | 폐암의 바이오마커 | |
| WO2011014083A3 (en) | Determination of the risk of distant metastases in surgically treated patients with non-small cell lung cancer in stage i-iiia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110410 |